Lung cancer
Conditions
Interventions
The clarithromycin group : A clarithromycin 200mg tablet is taken once per day for 6 months from immediately after the start of irradiation therapy.
Without clarithromycin group: without clarithrom
Sponsors
Yokohama City University Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age : >=20 or <= 75 years old 2. Performance status: 0-1 3. patient with lung cancer(stageII-III) for the purpose of chemoradiotherapy 4. patient by whom consent is got in written form about participation of the study
Exclusion criteria
Exclusion criteria: 1. patient who has merged mltiple organ failure including lungs of four or more internal organs 2.patient with idiopathic pulmonary fibrosis 3. patient who has past of chemotherapy, or chest radiotherapy in the past for other cancer 4. patient with active double cancer 5. patient who take corticosteroids 6. patient with pregnant, breast- feeding, and possibility of pregnancy 7. patient who are considered inappropriate by physicians in charge 8.patient for the purpose of stereotactic radiation therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| disease severity(Grade) of radiation pneumonitis with CTCAEver3.0 | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy: 1) Usefluness of various serum biomarker as indicator of disease severity of radiation pneumonitis. The biomarkers including, LDH, CRP, Type III procollagen N-terminal peptide (PIIIP), KL-6, SPD, and SPA, monocyte chemoattractant protein -1 (MCP-1), TGF-beta, IFN-gamma, HO-1, etc. 2) pulmonary function test 3) blood gas analysis Safety: adverse events, and their incidence. | — |
Countries
Japan
Contacts
Public ContactMasaharu Shinkai
Yokohama City University Medical Center Respiratory Disease Center
Outcome results
None listed